IHMF: Key Paper Bibliography
block.GIF (810 bytes)
Library Library
 
Download Acrobat Reader

To view some of the files in this section, you will require a version of Adobe Acrobat. This is free to download and is available on the Adobe Acrobat website.

Download PowerPoint Viewer

To view the PowerPoint presentations you will require Microsoft PowerPoint. You can download the latest PowerPoint viewer free from the Microsoft website.

You are welcome to download, view and use many of the slides contained in these presentations, however the original presenter and IHMF® must be suitably acknowledged for any use, for example in oral presentations or written material. Please also be aware that some slides contain graphs, illustrations or other content that may not be the copyright of the presenter or the IHMF® and permission ot use such material will need to be obtained from the copyright owner prior to use. Some of the slide presentations from the 13th IHMF® Annual Meeting are subject to 'restricted use' and the presentations to which this applies are labelled with the notice 'Restricted Use - please contact the presenter prior to any use of the content of this presentation'. These 'restricted use' presentations may only be viewed online or downloaded to view, and the original presenter must be contacted prior to any use.

If you are in any doubt about your use of this material, please contact the IHMF Secretariat.
Key Paper Bibliography
 

Herpes simplex virus
Varicella zoster virus
Cytomegalovirus
Human herpes virus-6, -7 and -8
Epstein-Barr virus
Other topics

 
  

Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men.

Kim HN, Meier A, Huang ML et al. J Infect Dis 2006; 194: 420–427
 
The relationship between condom use and herpes simplex virus acquisition.
Wald A, Langenberg AG, Krantz E et al. Ann Intern Med 2005; 143: 707–713
 
Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding.
Wald A, Selke S, Warren T et al. Sex Trans Dis 2006; 33: 529–533
 
Herpes simplex virus encephalitis in human UNC-93B deficiency.
Casrouge A, Zhang SY, Eidenschenk C et al. Science 2006; 314: 308–312
 
Complete genome sequence of cercopithecine herpesvirus 2 (SA8) and comparison with other simplexviruses
Tyler SD, Peters GA, Severini A. Virology 2005; 331: 429–440
 
Oral famciclovir for the suppression of recurrent genital herpes: the combined data from two randomized controlled trials
Tyring SK, Diaz-Mitoma F, Shafran SD, Locke LA, Sacks SL, Young CL. J Cutan Med Surg 2003; 7: 449–454
 
Homing in on the cellular immune response to HSV-2 in humans
Koelle DM, Gonzalez JC, Johnson AS. Am J Reprod Immunol 2005; 53: 172–181
 
The psychosocial impact of testing individuals with no history of genital herpes for herpes simplex virus type 2
Miyai T, Turner KR, Kent CK, Klausner J. Sex Transm Dis 2004; 31: 517–521
 
Calculating the contribution of herpes simplex virus type 2 epidemics to increasing HIV incidence: treatment implications
Blower S, Ma L. Clin Infect Dis 2004;39:S240–1247
 
CD4(+) T-cell responses to herpes simplex virus type 2 (HSV-2) glycoprotein G are type specific and differ in symptomatic and asymptomatic HSV-2-infected individuals
Eriksson K, Bellner L, Gorander S, Lowhagen GB, Tunback P, Rydberg K et al. J Gen Virol 2004;85:2139–12147
 
Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract
Gupta R, Wald A, Krantz E, Selke S, Warren T, Vargas-Cortes M et al. J Infect Dis 2004;190:1374–1381
 
Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy
Posavad CM, Wald A, Kuntz S, Huang ML, Selke S, Krantz E et al. J Infect Dis 2004;190:693–696
 
The Effects of Herpes Simplex Virus-2 on HIV-1 Acquisition and Transmission: A Review of Two Overlapping Epidemics
Corey L, Wald, A Celum CL, Quinn TC. J Acquir Immune Defic Syndr 2004;35:435–445
 
Once-daily valaciclovir to reduce the risk of transmission of genital herpes
Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T et al. N Engl J Med 2004;350:11–20
Comment in:
N Engl J Med 2004;350:67–68
 
The potential epidemiological impact of a genital herpes vaccine for women
Garnett GP, Dubin G, Slaoui M, Darcis T. Sex Transm Infect 2004;80:24–29 
 
Vaccination with a DNA vaccine encoding herpes simplex virus type 1 VP22 linked to antigen generates long-term antigen-specific CD8-positive memory T-cells and protective immunity
Kim TW, Hung CF, Kim JW, Juang J, Chen PJ, He L et al. Hum Gene Ther 2004;15:167–177 
 
Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India
Reynolds SJ, Risbud AR, Shepherd ME, Zenilman JM, Brookmeyer RS, Paranjape RS et al. J Infect Dis 2003;187:1513–1521
Comment in:
J Infect Dis 2003;187:1509–1512
 
Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture
Wald A, Huang ML, Carrell D, Selke S, Corey L. J Infect Dis 2003;188:1345–1351
 
Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response
Theil D, Derfuss T, Paripovic I, Herberger S, Meinl E, Schueler O et al. Am J Pathol 2003;163:2179–2184
 
Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2
Ashley-Morrow R, Krantz E, Wald A. Sex Transm Dis 2003;30:310–314
 
Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant
Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. JAMA 2003;289:203–209
 
Natural history of genital herpes simplex virus type 1 infection
Engelberg R, Carrell D, Krantz E, Corey L, Wald A. Sex Transm Dis 2003;30:174–177
 
Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant
Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. JAMA 2003;289:203–209
 
Herpes simplex 2 risk among women in a polygynous setting in rural West Africa
Halton K, Ratcliffe AA, Morison L, West B, Shaw M, Bailey R, Walraven G. AIDS 2003;17:97–103
 
Herpes simplex virus type 1 infection: a sexually transmitted infection of adolescence?
Cowan FM, Copas A, Johnson AM, Ashley R, Corey L, Mindel A. Sex Transm Infect 2002;78:346–348
 
Challenges in genital herpes simplex virus management
Corey L. J Infect Dis 2002;186 Suppl 1:S29–S33
 
Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review
Smith JS, Robinson NJ. J Infect Dis 2002;186 Suppl 1:S3–S28
 
Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection
Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Clin Infect Dis 2002;34:944–948
 
Genital Shedding of Herpes Simplex Virus among Men
Wald A, Zeh J, Selke S, Warren T, Ashley R, Corey L. J Infect Dis 2002;186:S34–39
 
Herpes simplex virus type 2-specific CD8 cytotoxic T lymphocyte cross-reactivity against prevalent HLA class I alleles
Koelle DM, Chen HB, McClurkan CM, Petersdorf EW. Blood 2002;99:3844–3847
 
Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis
Wald A, Link K. J Infect Dis 2002;185:45–52
 
Clinical uses of herpes simplex virus type-specific serology
Munday PE, Mullan HM. Int J STD AIDS 2001;12:784–788
 
Cutting edge: a NK complex-linked locus governs acute versus latent herpes simplex virus infection of neurons
Pereira RA, Scalzo A, Simmons A. J Immunol 2001;166:5869–5873 on-line.gif (604 bytes)
 
Demographic rather than behavioral risk factors predict herpes simplex virus type 2 infection in sexually active adolescents
Sucato G, Celum C, Dithmer D, Ashley R, Wald A. Pediatr Infect Dis J 2001;20:422–426 on-line.gif (604 bytes)
 
Incidence of herpes simplex virus type 2 infection in the United States
GL Armstrong, J Schillinger, L Markowitz et al. Am J Epidemiol 2001;153:912–920
 
Dendritic cell vaccination protects mice against lethality caused by genital herpes simplex virus type 2 infection
E Schon, AM Harandi, I Nordstrom, J Holmgren, K Eriksson. J Reprod Immunol 2001;50:87–104
 
Differential roles of B cells and IFN-gamma-secreting CD4(+) T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice
AM Harandi, B Svennerholm, J Holmgren, K Eriksson. J Gen Virol 2001;82:845–853
 
Diagnostic utility of a multiplex herpesvirus PCR assay performed with cerebrospinal fluid from human immunodeficiency virus-infected patients with neurological disorders
C Quereda, I Corral, F Laguna et al. J Clin Microbiol 2000;38:3061–3067
 
Antigen-specific T cells localize to the uterine cervix in women with genital herpes simplex virus type 2 infection
DM Koelle, M Schomogyi, L Corey. J Infect Dis 2000;182:662–670
 
Genital Herpes and public health: addressing a global problem
L Corey, HH Handsfield. JAMA 2000;283:791–794 
 
Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: Effects of hormonal contraception, pregnancy and vitamin A deficiency
SB Mostad, JK Kreiss, AJ Ryncarz et al. J Infect Dis 2000;181:58–63
 
Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons
A Wald, J Zeh, S Selke et al. N Engl J Med 2000;342:844–850
 
Herpes simplex virus type 2 shedding in human immunodeficiency viru-negative men who have sex with men: frequency, patterns and risk factors
MR Krone, A Wald, SR Tabet et al. Clin Infect Dis 2000;30:261–267
 
Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod
RL Miller, LM Imbertson, MJ Reiter, JF Gerster. Antiviral Res 1999;44:31–42 on-line.gif (604 bytes)
 
A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group
AG Langenberg, L Corey, RL Ashley et al N Engl J Med 1999;341:1432–1438
   
  
Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992–2002
Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. J Infect Dis 2005; 191: 2002–2007
 
Varicella vaccination of children in the United States: assessment after the first decade 1995–2005
Grose C. J Clin Virol 2005; 33: 89–95
 
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD et al. N Engl J Med 2005; 352: 2271–2284
 
Simian varicella: a model for human varicella zoster virus infections
Gray WL. Rev Med Virol 2004;10 [E-pub ahead of print]
 
Latent herpesvirus infection in human trigeminal ganglia causes chronic immune response
Theil D, Derfuss T, Paripovic I, Herberger S, Meinl E, Schueler O et al. Am J Pathol 2003;163:2179–2184
 
Varicella vaccination in England and Wales: cost-utility analysis
Brisson M, Edmunds WJ. Arch Dis Child 2003;88:862–869
     
Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV
Brisson M, Edmunds WJ, Gay NJ. J Med Virol 2003;70 Suppl 1:S31–S37
     
Outbreak of varicella at a day-care center despite vaccination
Galil K, Lee B, Strine T, Carraher C, Baughman AL, Eaton M et al. N Engl J Med 2002;347:1909–1915
Comment in: N Engl J Med 2002;347:1962–1963
     
Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study
Thomas SL, Wheeler JG, Hall AJ. Lancet 2002;360:678–682
     
Antiviral treatment of varicella in pediatric practice in the Latium region of Italy: results of an observational study
Volpi A, Gentile G, Pica F, Suligoi B; Slavip study group. Pediatr Infect Dis J 2002;21:739–743
     
The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales
WJ Edmunds, M Brisson, JD Rose. Vaccine 2001;19:3076–3090
 
Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics
Acosta EP, Balfour HH, Jr. Antimicrob Agents Chemother 2001;45:2771–2774   on-line.gif (604 bytes)
   
Post-licensure safety surveillance for varicella vaccine
RP Wise, ME Salive, MM Braun et al. JAMA 2000;284:1271–1290
 
Quantitation of latent varicella-zoster virus and herpes simplex virus genomes in human trigeminal ganglia
SR Pevenstein, RK Williams, D McChesney et al. J Virol 1999;73:10514–10518   on-line.gif (604 bytes)
   
  
Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis.
Humar A. Transplantation 2006;82:S9–S14
 		  
Repertoire, diversity, and differentiation of specific CD8 T-cells are associated with immune protection against human cytomegalovirus disease.
Sacre K, Carcelain G, Cassoux N, Fillet AM, Costagliola D, Vittecoq D et al. J Exp Med 2005; 201: 1999–2010.
 		  
Congenital Cytomegalovirus Infection: Association between Virus Burden in Infancy and Hearing Loss.
Boppana SB, Fowler KB, Pass RF, Rivera LB, Bradford RD, Lakeman FD et al. J Pediatr. 2005;146:817–823
 		  
The clinical impact of ganciclovir prophylaxis on the occurrence of bacteremia in orthotopic liver transplant recipients
Munoz-Price LS, Slifkin M, Ruthazer R, Poutsiaka DD, Hadley S, Freeman R et al. Clin Infect Dis 2004;39:1293–1299.
 		  
Genetic content of wild-type human cytomegalovirus
Dolan A, Cunningham C, Hector RD, Hassan-Walker AF, Lee L, Addison C, et al. J Gen Virol 2004;85:1301–1312.
 		  
Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy
Deayton JR, Prof Sabin CA, Johnson MA, Emery VC, Wilson P, Griffiths PD. Lancet 2004;363:2116–2121.
 		  
Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections
Razonable RR, Paya CV. Herpes 2003;10:60–65
 
Persistent and selective deficiency of CD4+ T-cell immunity to cytomegalovirus in immunocompetent young children
Hecker M, Qiu D, Marquardt K, Bein G, Hackstein H. Vox Sang 2004;86:41–44
       
Continuous cytomegalovirus seroconversion in a large group of healthy blood donors
Tu W, Chen S, Sharp M, Dekker C, Manganello AM, Tongson EC et al. J Immunol 2004;172:3260–3267
       
Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors
Winston DJ, Busuttil RW. Transplantation 2004;77:305–308
       
Human cytomegalovirus inhibits differentiation of monocytes into dendritic cells with the consequence of depressed immunological functions
Gredmark S, Soderberg-Naucler C. J Virol 2003;77:10943–10956
       
Effect of anti-cytomegalovirus therapy on the incidence of immune recovery uveitis in AIDS patients with healed cytomegalovirus retinitis
Song MK, Azen SP, Buley A, Torriani F, Cheng L, Chaidhawangul S et al. Am J Ophthalmol 2003;136:696–702
       
Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial
Kimberlin DW, Lin CY, Sanchez PJ, Demmler GJ, Dankner W, Shelton M et al. J Pediatr 2003;143:16–25
       
Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus
Wang X, Huong SM, Chiu ML, Raab-Traub N, Huang ES. Nature 2003;424:456–461
       
Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study
Smieja M, Gnarpe J, Lonn E, Gnarpe H, Olsson G, Yi Q et al. Circulation 2003;107:251–257
       
The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome
Davison AJ, Dolan A, Akter P, Addison C, Dargan DJ, Alcendor DJ et al. J Gen Virol 2003;84:17–28  
       
Maternal immunity and prevention of congenital cytomegalovirus infection
Fowler KB, Stagno S, Pass RF. JAMA 2003;289:1008–1011  
Human cytomegalovirus terminase as a target for antiviral chemotherapy
Bogner E. Rev Med Virol 2002;12:115–127  
   
Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial
Paya CV, Wilson JA, Espy MJ, Sia IG, DeBernardi MJ, Smith TF et al. J Infect Dis 2002;185:854–860  
 
CMV and blood transfusions
Roback JD. Rev Med Virol 2002;12:211–219  
 
Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation
Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D et al. Blood 2002;99:1159–1164  
 
Prevention of cytomegalovirus infection and disease after lung transplantation: results using a unique regimen employing delayed ganciclovir
Brumble LM, Milstone AP, Loyd JE, Ely EW, Pierson RN, 3rd, Gautam S et al. Chest 2002;121:407–414  
 
Complete replication of human cytomegalovirus in explants of first trimester human placenta
Gabrielli L, Losi L, Varani S, Lazzarotto T, Eusebi V, Landini MP. J Med Virol 2001;64:499–504  
 
Chlamydia pneumoniae and cytomegalovirus seropositivity, inflammatory markers, and the risk of myocardial infarction at a young age
Gattone M, Iacoviello L, Colombo M, Castelnuovo AD, Soffiantino F, Gramoni A et al. Am Heart J 2001;142:633–640  
 
Chlamydia pneumoniae-induced transactivation of the major immediate early promoter of cytomegalovirus: potential synergy of infectious agents in the pathogenesis of atherosclerosis
C Wanishsawad, YF Zhou, SE Epstein. J Infect Dis 2000;181:787–790
 
Cytomegalovirus antigenaemia directed pre-emptive prophylaxis with oral versus i.v. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial
N Singh, DL Paterson, T Gayowski et al. Transplantation 2000;70:717–722
 
Histopathological detection of owl's eye inclusions is still specific for cytomegalovirus in the era of human herpesviruses 6 and 7
FM Mattes, JE McLaughlin, VC Emery et al J Clin Pathol 2000;53:612–614
 
Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation
VC Emery, CA Sabin, AV Cope et al Lancet 2000;355:2032–2036
 
Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy
VC Emery, PD Griffiths. Proc Natl Acad Sci USA 2000;97:8039–8044   on-line.gif (604 bytes)
 
Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants
AP Limaye, L Corey, DM Koelle et al. Lancet 2000;356:645–649
 
Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4-positive T cells
R Tomazin, J Boname, NR Hegde et al. Nat Med 1999;5:1039–1043
 
Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group
A Kovacs, M Schluchter, K Easley et al. N Engl J Med 1999:341:77–84
 
Valaciclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valaciclovir Cytomegalovirus Prophylaxis Transplantation Study Group
D Lowance, HH Neumayer, CM Legendre et al. N Engl J Med 1999;340:1462–1470
   
  

Characteristics and acquisition of human herpesvirus (HHV) 7 infections in relation to infection with HHV-6.

Hall CB, Caserta MT, Schnabel KC et al. J Infect Dis 2006; 193: 1063–1069
 

Transmission of human herpesvirus 8 by blood transfusion

Hladik W, Dollard SC, Mermin J et al. N Engl J Med 2006; 355: 1331–1338
 

Transmission of integrated human herpesvirus 6 through stem cell transplantation: implications for laboratory diagnosis.

Clark DA, Nacheva EP, Leong HN et al. J Infect Dis 2006; 193: 912–916
 
Host immunogenetics and control of human herpesvirus-8 infection
Brown EE, Fallin MD, Goedert JJ et al. J Infect Dis 2006; 193: 1054–1062
 
Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma
Guihot A, Dupin N, Marcelin AG et al. J Infect Dis 2006; 194: 1078–1088
 
Human herpesviruses-6 and -7 each cause significant neurological morbidity in Britain and Ireland
Ward KN, Andrews NJ, Verity CM, Miller E, Ross EM. Arch Dis Child 2005; 90: 619–623
 
Correlates of human herpes virus-8 and herpes simplex virus type 2 infections in northern Cameroon
Volpi A, Sarmati L, Suligoi B, Montano M, Rezza G, Andreoni MJ. J Med Virol 2004;74:467–472
 
Mother-to-child transmission of human herpesvirus-8 in South Africa
Dedicoat M, Newton R, Alkharsah KR, Sheldon J, Szabados I, Ndlovu B  et al. J Infect Dis 2004;190:1068–1075
 
Prevalence of human herpesvirus-8 salivary shedding in HIV increases with CD4 count
Gandhi M, Koelle DM, Ameli N, Bacchetti P, Greenspan JS, Navazesh M  et al. J Dent Res 2004;83:639–643
 
Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients
Marcelin AG, Roque-Afonso AM, Hurtova M, Dupin N, Tulliez M, Sebagh M et al. Liver Transpl 2004;10:295–300   
 
Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi's sarcoma pathogenesis
Grundhoff A, Ganem D. J Clin Invest 2004;113:124–136   
 
Split genes and their expression in Kaposi's sarcoma-associated herpesvirus
Zheng ZM. Rev Med Virol 2003;13:173–184   
 
Human herpesvirus (HHV)-6 and HHV-7: two closely related viruses with different infection profiles in stem cell transplantation recipients
Boutolleau D, Fernandez C, Andre E, Imbert-Marcille BM, Milpied N, Agut H et al. J Infect Dis 2003;187:179–186  
 
Assessment of a combined testing strategy for detection of antibodies to human herpesvirus 8 (HHV-8) in persons with Kaposi's sarcoma, persons with asymptomatic HHV-8 infection, and persons at low risk for HHV-8 infection
Casper C, Krantz E, Taylor H, Dalessio J, Carrell D, Wald A et al. J Clin Microbiol 2002;40:3822–3825  
 
Primary human herpesvirus 8 infection in immunocompetent children
Andreoni M, Sarmati L, Nicastri E, El Sawaf G, El Zalabani M, Uccella I et al. JAMA 2002;287:1295–1300  

 
HHV-8 infection: a model for reactivation and transmission
Corey L, Brodie S, Huang ML, Koelle DM, Wald A. Rev Med Virol 2002;12:47–63  
 
Prevalence, incidence and correlates of HHV-8/KSHV infection and Kaposi's sarcoma in renal and liver transplant recipients
Andreoni M, Goletti D, Pezzotti P, Pozzetto A, Monini P, Sarmati L et al. J Infect 2001;43:195–199  
 
Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients
Zerr DM, Gooley TA, Yeung L, Huang ML, Carpenter P, Wade JC et al. Clin Infect Dis 2001;33:763–771  
 
Human herpesvirus-6 and -7 in transplantation
DH Dockrell, CV Paya. Rev Med Virol 2001;11:23–36
 
Kaposi's sarcoma before and during a human immunodeficiency virus epidemic in Tanzanian children
H Amir, EE Kaaya, KP Manji, G Kwesigabo, P Biberfeld. Pediatr Infect Dis 2001;20:518–521
 
Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection
MJ Cannon, SC Dollard, DK Smith et al. N Engl J Med 2001;344:637–643
 
Human herpesvirus 8 infection and Kaposi's sarcoma among human immunodeficiency virus-infected and -uninfected women
RM Greenblatt, LP Jacobson, AM Levine et al. J Infect Dis 2001;183:1130–1134
 
Seroepidemiology of human herpesvirus 8 among young men who have sex with men. The Seattle Young Men's Survey Team
C Diamond , H Thiede, T Perdue, D MacKellar, LA Valleroy, L Corey. Sex Transm Dis 2001;26:176–183
  
Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis
L Coscoy, D Ganem. Proc Natl Acad Sci USA 2000;97:8051–8056   on-line.gif (604 bytes)
 
Human herpesvirus 8 infections in the Amsterdam Cohort Studies (1984-1997): analysis of seroconversions to ORF65 and ORF73
J Goudsmit, N Renwick, NH Dukers et al. Proc Natl Acad Sci USA 2000;97:4838–4843
 
Invasion by human herpesvirus 6 and human herpesvirus 7 of the central nervous system in patients with neurological signs and symptoms
T Yoshikawa, M Ihira, K Suzuki et al. Arch Dis Child 2000;83:170–171
 
Mucosal shedding of human herpesvirus 8 in men
J Pauk, ML Huang, SJ Brodie et al. N Engl J Med 2000;343:1411–1413
 
Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population
S Plancoulaine, L Abel, M van Beveren et al. Lancet 2000;356:1062–1065
 
The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir
DC Brennan, GA Storch, GG Singer et al. J Infect Dis 2000;181:1557–1561
 
Non-malignant disease associated with human herpesvirus 8 reactivation in patients who have undergone autologous peripheral blood stem cell transplantation
M Luppi, P Barozzi, TF Schulz et al. Blood 2000;96:2355–2357
 
Histopathological detection of owl's eye inclusions is still specific for cytomegalovirus in the era of human herpesviruses 6 and 7
FM Mattes, JE McLaughlin, VC Emery, DA Clark, PD Griffiths. J Clin Pathol 2000;53:612–614
  
Human herpesvirus 6
DA Clark. Rev Med Virol 2000;10:155–173
 
Human herpesvirus 6 is associated with cytomegalovirus reactivation in liver transplant recipients
A Humar, G Malkan, G Moussa et al. J Infect Dis 2000;181:1450–1453
 
Reactivation of human herpesvirus 6 by infection of human herpesvirus 7
K Tanaka-Taya, T Kondo, N Nakagawa et al. J Med Virol 2000;60:284–289  
 
Successful treatment of human herpesvirus-6 encephalitis after bone marrow transplantation
W Bethge, R Beck, G Jahn et al. Bone Marrow Transplant 1999;24:1245–1248
   
Human herpesviruses 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus
PD Griffiths, M Ait-Khaled, CP Bearcroft et al. J Med Virol 1999;59:496–501  
  
p53 inhibition by the LANA protein of KSHV protects against cell death
J Friborg Jr, W Kong, MO Hottiger, GJ Nabel. Nature 1999;402:889–894
  
  

A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder

Humar A, Hebert D, Davies HD et al. Transplantation 2006;81:856–861

  
Post-transplant lymphoproliferative disorders
Gottschalk S, Rooney CM, Heslop HE. Annu Rev Med 2005; 56: 29–44
Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era
Ghobrial IM, Habermann TM, Ristow KM, Ansell SM, Macon W, Geyer SM et al. Leuk Lymphoma 2005; 46: 191–196
 
Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections
Razonable RR, Paya CV. Herpes 2003;10:60–65
 		  
Epstein-Barr virus-associated cancers: aetiology and treatment
Lopes V, Young LS, Murray PG. Herpes 2003;10:78–82
Epstein-Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir
Walling DM, Flaitz CM, Nichols CM. J Infect Dis 2003;188:883–890
Epstein-Barr virus and oncogenesis: from latent genes to tumours
Young LS, Murray PG. Oncogene 2003;22:5108–5121
Treatment of Epstein–Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T-cells
Haque T, Wilkie GM, Taylor C, Amlot PL, Murad P, Iley A et al. Lancet 2002;360:436–442
   
A systematic study of Epstein-Barr virus serologic assays following acute infection
Rea TD, Ashley RL, Russo JE, Buchwald DS. Am J Clin Pathol 2002;117:156–161  
   
The immunology of Epstein-Barr virus infection
Moss DJ, Burrows SR, Silins SL, Misko I, Khanna R. Philos Trans R Soc Lond B Biol Sci 2001;356:475–488  
 
Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients
Preiksaitis JK, Keay S. Clin Infect Dis 2001;33 Suppl 1:S38–S46